One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis
WeiZhangMD, PhD, MSaJaime LynnSpeiserMSc, PhDbFanYeMD, PhDaMichael Y.TsaiPhDcMiguelCainzos-AchiricaMD, MPH, PhDdKhurramNasirMD, MPH, MScdDavid M.HerringtonMD, MHSaMichael D.ShapiroDO, MCRa
doi : 10.1016/j.jacc.2021.07.016
Volume 78, Issue 11, 14 September 2021, Pages 1083-1094
Little is known about the relationship between lipoprotein (a) [Lp(a)] and high-sensitivity C-reactive protein (hsCRP) and their joint association with atherosclerotic cardiovascular disease (ASCVD).
Lifetime Risk Estimation in Atherosclerotic Cardiovascular Disease: Where Inflammation Meets Lipoprotein(a)?
XavierRosselloMD, PhD
doi : 10.1016/j.jacc.2021.07.035
Volume 78, Issue 11, 14 September 2021, Pages 1095-1096
Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy
Antoniode MarvaoMBChB, PhDaKathryn A.McGurkPhDbSean L.ZhengBMBChbcMarjolaThanajPhDaWenjiaBaiPhDdeJinmingDuanPhDadfCarloBiffiPhDadFrancescoMazzarottoPhDbcghBenStattonMScaTimothy J.W.DawesMB BChir, PhDabNicolòSavioliPhDaBrian P.HallidayMBChB, PhDbcXiaoXuPhDbcRachel J.BuchanMScbcA. JohnBaksiMBBS, PhDbcMarinaQuinlanMScaPawe?TokarczukPhDaUpasanaTayalBMBCh, PhDbcCatherineFrancisBMBCh, PhDbcNicolaWhiffinPhDbciPantazis I.TheotokisMScaXiaoleiZhangPhDbMikyungJangPhDbcAlaineBerryMScaAntonisPantazisMDbcPaul J.R.BartonPhDabcDanielRueckertPhDdjSanjay K.PrasadMDbcRoddyWalshPhDkCarolyn Y.HoMDlStuart A.CookMBBS, PhDabcmnJames S.WareMB BChir, PhDabc?Declan P.O’ReganMBBS, PhDa?
doi : 10.1016/j.jacc.2021.07.017
Volume 78, Issue 11, 14 September 2021, Pages 1097-1110
Hypertrophic cardiomyopathy (HCM) is caused by rare variants in sarcomere-encoding genes, but little is known about the clinical significance of these variants in the general population.
Hypertrophic Cardiomyopathy in the General Population: Leveraging the UK Biobank Database and Machine Learning Phenotyping?
Linnea M.BaudhuinPhD
doi : 10.1016/j.jacc.2021.07.036
Volume 78, Issue 11, 14 September 2021, Pages 1111-1113
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy
Steven E.NissenMDabHoward G.HutchinsonMDcTracy Y.WangMD, MHS, MScdChristie M.BallantyneMDeSaraTravisBSfMelanieMorrisBAcWilliamMillerMDfJenniferHynsonBAfKathyWolskiMPHabPaul MRidkerMDg
doi : 10.1016/j.jacc.2021.06.048
Volume 78, Issue 11, 14 September 2021, Pages 1114-1123
Although statins reduce cardiovascular morbidity and mortality, only about one-half of eligible patients receive treatment. Safe and appropriate consumer access to statins could have a significant positive public health impact.
Should Cardiovascular Preventive Therapy Be Over-the-Counter??
Neha J.PagidipatiMD, MPHaEric D.PetersonMD, MPHb
doi : 10.1016/j.jacc.2021.07.020
Volume 78, Issue 11, 14 September 2021, Pages 1124-1126
Innate Lymphoid Cells Promote Recovery of Ventricular Function After Myocardial Infarction
XianYuMD, PhDab?Stephen A.NewlandPhDa?Tian X.ZhaoMD, PhDaYuningLuMD, PhDaAndrew S.SagePhDaYanyiSunMD, PhDcRouchelle S.SriranjanPhDaMarcella K.L.MaPhDdBrian Y.H.LamPhDdMeritxellNusPhDaJames E.HarrisonBScaSimon J.BondPhDeXiangChengMD, PhDbJean-SébastienSilvestrePhDcJames H.F.RuddMD, PhDaJosephCheriyanMBChB, MAefZiadMallatMD, PhDac
doi : 10.1016/j.jacc.2021.07.018
Volume 78, Issue 11, 14 September 2021, Pages 1127-1142
Innate lymphoid cells type 2 (ILC2s) play critical homeostatic functions in peripheral tissues. ILC2s reside in perivascular niches and limit atherosclerosis development.
Innate Lymphoid Cells Participate in Myocardial Inflammation After Ischemia?
MatthiasNahrendorfMD, PhD
doi : 10.1016/j.jacc.2021.07.013
Volume 78, Issue 11, 14 September 2021, Pages 1143-1144
Medial Arterial Calcification: JACC State-of-the-Art Review
PeterLanzerMDaFadil M.HannanDPhilbJan D.LanzerMDcdeJanJanzenMDfPaoloRaggiMDgDominicFurnissDM, MBBChhMirjamSchuchardtPhDiRajeshThakkerScDjPak-WingFokPhDkJulioSaez-RodriguezPhDcAngelMillanPhDlYuSatoMDmRobertoFerraresiMDnRenuVirmaniMDmCynthiaSt. HilairePhDopq
doi : 10.1016/j.jacc.2021.06.049
Volume 78, Issue 11, 14 September 2021, Pages 1145-1165
Medial arterial calcification (MAC) is a chronic systemic vascular disorder distinct from atherosclerosis that is frequently but not always associated with diabetes mellitus, chronic kidney disease, and aging. MAC is also a part of more complex phenotypes in numerous less common diseases. The hallmarks of MAC include disseminated and progressive precipitation of calcium phosphate within the medial layer, a prolonged and clinically silent course, and compromise of hemodynamics associated with chronic limb-threatening ischemia. MAC increases the risk of complications during vascular interventions and mitigates their outcomes. With the exception of rare monogenetic defects affecting adenosine triphosphate metabolism, MAC pathogenesis remains unknown, and causal therapy is not available. Implementation of genetics and omics-based approaches in research recognizing the critical importance of calcium phosphate thermodynamics holds promise to unravel MAC molecular pathogenesis and to provide guidance for therapy. The current state of knowledge concerning MAC is reviewed, and future perspectives are outlined.
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review
AmbarishPandeyMD, MSCSaSanjiv J.ShahMDbJavedButlerMD, MPH, MBAcDean L.KelloggJrMD, PhDdGregory D.LewisMDeDaniel E.FormanMDfRobert J.MentzMDgBarry A.BorlaugMDhMarc A.SimonMDfJulio A.ChirinosMDiRoger A.FieldingPhDjElenaVolpiMDkAnthony J.A.MolinaPhDlMark J.HaykowskyPhDmFloraSamMDnBret H.GoodpasterPhDoAlain G.BertoniMD, MPHpJamie N.JusticePhDpJames P.WhitePhDqJingzhoneDingPhDpScott L.HummelMD, MSrNathan K.LeBrasseurPhDhGeorge E.TaffetMDsIraklis I.PipinosMDtDalaneKitzmanMDp
doi : 10.1016/j.jacc.2021.07.014
Volume 78, Issue 11, 14 September 2021, Pages 1166-1187
Exercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals. The recent recognition that HFpEF is likely a systemic, multiorgan disorder that shares characteristics with other common, difficult-to-treat, aging-related disorders suggests that novel insights may be gained from combining knowledge and concepts from aging and cardiovascular disease disciplines. This state-of-the-art review is based on the outcomes of a National Institute of Aging–sponsored working group meeting on aging and EI in HFpEF. We discuss aging-related and extracardiac contributors to EI in HFpEF and provide the rationale for a transdisciplinary, “gero-centric” approach to advance our understanding of EI in HFpEF and identify promising new therapeutic targets. We also provide a framework for prioritizing future research, including developing a uniform, comprehensive approach to phenotypic characterization of HFpEF, elucidating key geroscience targets for treatment, and conducting proof-of-concept trials to modify these targets.
How Cardiovascular Disease Fellows Can Promote Diversity and Inclusion in Cardiology: Doing Our Part
Joyce N.NjorogeMDaQuentin R.YoumansMD, MScbSarahChuziMD, MScb
doi : 10.1016/j.jacc.2021.07.012
Volume 78, Issue 11, 14 September 2021, Pages 1188-1192
RESPONSE: Promoting Equity, Diversity, and Inclusion in Cardiology: Thinking Broadly, Acting Practically
Robert O.RoswellMD
doi : 10.1016/j.jacc.2021.07.026
Volume 78, Issue 11, 14 September 2021, Pages 1191-1192
A Transatlantic Comparison of Patient-Reported Access to and Use of Aspirin in Contemporary Preventive Cardiology
Alan P.JacobsenMB, BCh, BAOZi LunLimMB, BCh, BAOBlairChangBAKaleb D.LambethMDThomas M.DasMDColinGorryMB, BCh, BAOMichaelMcCagueMScWilliamWijnsMD, PhDPatrick W.J.C.SerruysMD, PhDRoger S.BlumenthalMDSeth S.MartinMD, MHSJohn W.McEvoyMB, BCh, BAO, MHS
doi : 10.1016/j.jacc.2021.07.015
Volume 78, Issue 11, 14 September 2021, Pages 1193-1195
Calcium Score to Specify Assessment of Low-Flow Aortic Stenosis Severity
GudrunLammMDJohannAuerMD
doi : 10.1016/j.jacc.2021.06.047
Volume 78, Issue 11, 14 September 2021, Page e71
Reply: Calcium Score to Specify Assessment of Low-Flow Aortic Stenosis Severity
GuillaumeJeanMDPhilippePibarotDVM, PhDMarie-AnnickClavelDVM, PhD
doi : 10.1016/j.jacc.2021.07.011
Volume 78, Issue 11, 14 September 2021, Page e73
